Cigna plans to remove AbbVie’s blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement in 2025, and recommend less-pricey biosimilar versions of ...

Pharmalittle: We’re reading about Zepbound pricing caveats, PBM congressional testimony, and more Zepbound pricing changes may not expand access as much as Lilly has indicated Alex Hogan/STAT ...

The 50-year-old is now on Novo Nordisk ’s Wegovy, but worries because it is less effective. Studies have shown Wegovy helps people lose less weight, on average, than Zepbound.

Patients taking the GLP-1 weight loss drug Zepbound face mandatory switch to Wegovy after CVS Caremark removed the Eli Lilly medication from its preferred coverage list, citing rising costs.

Wegovy will now be the GLP-1 weight loss drug of choice under plans that are managed by CVS Caremark. If they stay on Zepbound for their GLP-1 weight loss treatment, they will have to pay full ...

Eli Lilly is offering vials of its weight-loss drug Zepbound to patients at a discount — but only if they skip their insurance. Novo Nordisk is now discounting Wegovy for cash customers too.

Eli Lilly, the maker of Zepbound, announced Tuesday it will begin selling the weight loss drug directly to consumers through the company's direct pharmacy, LillyDirect.

Zepbound is a glucagon-like peptide 1 drug that reduces appetite and food intake. The drug's active ingredient, tirzepatide, is marketed as Zepbound for weight loss and Mounjaro as a diabetes ...

Trizepatide (Zepbound), on the other hand, mimics two different hormones — GLP-1 and GIP — both of which the body produces after one eats. GIP bolsters how the body processes sugar and fat.

Those who took Zepbound lost on average of 50 pounds, compared to 33 pounds lost among those who took Wegovy. That’s the equivalent of losing 20% of body weight with Zepbound, versus nearly 14% ...